Clinical Trial Update: Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating the efficacy of a 13-valent pneumococcal conjugate vaccine in adults has completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease
• Pneumococcal Pneumonia

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumonia, Pneumococcal, Pneumococcal Infections | Phase 4 | Status: COMPLETED | Results posted: 2014-10-06